Caribou Biosciences to Evaluate Strategic Alternatives
Caribou said it plans to stop developing vispa-cel and CB-011 while it seeks strategic alternatives amid financing constraints.
TL;DR
- Caribou announced on October 6 that it plans to discontinue its two allogeneic CAR-T programs, vispa-cel and CB-011.
- The company said it is exploring strategic alternatives and will reduce its workforce and costs.
- Its release reported $113.8 million in cash, equivalents, and marketable securities as of June 30, 2026.
Caribou Biosciences said it is exploring strategic alternatives and plans to discontinue further development of vispa-cel, for relapsed or refractory B-cell non-Hodgkin lymphoma, and CB-011, for relapsed or refractory multiple myeloma. The company announced the decision on October 6. [1] [2]
The company linked the decision to difficulty securing enough capital to advance the programs and said it would reduce its workforce and operating costs. Its release reported $113.8 million in cash, cash equivalents, and marketable securities at June 30, 2026. [1] [2]
Drug Discovery World’s coverage likewise described the two program cancellations as a financing-driven retreat. The two candidates were allogeneic, or donor-derived, CAR-T programs; their development status should not be confused with a regulatory safety finding about the CAR-T class. [1] [2]
Caribou said it would review options for the business and its assets. The timing and form of any transaction, and the disposition of ongoing program activities, remain uncertain; no new clinical efficacy conclusion is established by the corporate decision. [1] [2]
Why it matters
The decision removes two clinical-stage allogeneic CAR-T programs from active development and illustrates how financing conditions can determine whether late-stage cell-therapy plans proceed.
Editor's note
Company announcement and independent trade coverage agree on the discontinuation and financing context. No medical guidance is offered.